WO2017057450A1 - Peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire, et son utilisation - Google Patents

Peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire, et son utilisation Download PDF

Info

Publication number
WO2017057450A1
WO2017057450A1 PCT/JP2016/078607 JP2016078607W WO2017057450A1 WO 2017057450 A1 WO2017057450 A1 WO 2017057450A1 JP 2016078607 W JP2016078607 W JP 2016078607W WO 2017057450 A1 WO2017057450 A1 WO 2017057450A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
cells
biliary tract
tract cancer
amino acid
Prior art date
Application number
PCT/JP2016/078607
Other languages
English (en)
Japanese (ja)
Inventor
英作 近藤
齋藤　憲
Original Assignee
国立大学法人新潟大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人新潟大学 filed Critical 国立大学法人新潟大学
Priority to JP2017543480A priority Critical patent/JP6839447B2/ja
Publication of WO2017057450A1 publication Critical patent/WO2017057450A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Definitions

  • the present invention relates to a peptide having an accumulation property specific to biliary tract cancer and use thereof.
  • Biliary tract cancer is a cancer composed of bile duct cancer, gallbladder cancer, and duodenal papilla cancer.
  • the number of deaths from bile duct cancer and gallbladder cancer in Japan is about 8,900 men and about 9,300 women in 2013.
  • the number of bile duct cancer and gallbladder cancer cases (national estimates) in 2010 was about 11,300 males and about 11,300 females, accounting for 2% and 3% of the total cancer cases, respectively.
  • about 20% of the patients can apply surgery, and the survival rate five years after surgery is about 30%.
  • Biliary tract cancer has few subjective symptoms at an early stage and may progress to some extent when symptoms such as jaundice, white stool, jaundice urine, abdominal pain appear, and early detection is important in treatment .
  • the biliary tract cancer in the present specification includes bile duct epithelium-derived adenocarcinoma, adenosquamous cell carcinoma, and intrahepatic cholangiocellular carcinoma in terms of histopathology.
  • Tests and diagnostic methods for biliary tract cancer include blood biochemical examination, abdominal ultrasonography, abdominal contrast CT examination, endoscopic retrograde pancreatobiliary imaging (ERCP: Examples include endoscopic retrograde cholangiopancreatography and FDG-PET (Fluorodeoxy glucose-Positron Emission Tomography) inspection.
  • ERCP endoscopic retrograde pancreatobiliary imaging
  • FDG-PET Fluorodeoxy glucose-Positron Emission Tomography
  • cell membrane-permeable (cell-absorbing) peptides such as Tat, penetratin, and polyargineine have attracted attention.
  • these peptides are widely and non-selectively absorbed without distinction between normal cells or normal tissues and tumor cells or tumor tissues, treatment of malignant tumors requiring target-selective drug transport DDS (Drag Delivery) Application to the (System) tool is difficult in that it causes serious side effects.
  • cell membrane-permeable (cell-absorbing) peptides such as Tat which are widely used in experimental systems worldwide, are known to cause accumulation in the liver (see, for example, Non-Patent Document 1).
  • Cyclic RGD is the only medicinal peptide. Cyclic RGD targets ⁇ v ⁇ 3 integrin, which has been reported to be highly expressed in endothelial cells (and some tumor cells) in new blood vessels or existing blood vessels, and its action point for enhancing vascular permeability. Therefore, it is applied as an imaging agent or a DDS agent in the form of simultaneous use with other drugs, not alone (see, for example, Patent Document 1).
  • the determination criterion of the inspection result is the determination of an abnormal shadow.
  • the accuracy of shadow determination including the spread of lesions.
  • the cyclic RGD described in Patent Document 1 is not a peptide that targets tumor cells and tumor tissue itself, and thus is novel in terms of a peptide having the ability to directly capture cancer. There was still room for improvement.
  • the present invention has been made in view of the above circumstances, and provides a novel peptide having a specific accumulation property by directly acting on biliary tract cancer cells and tissues.
  • the present invention includes the following aspects.
  • the peptide according to [1] or [2] further comprising cysteine residues at the N-terminus and C-terminus.
  • [4] The peptide according to any one of [1] to [3], which is a retro-inverso type substituted with a D-form amino acid.
  • [5] A nucleic acid encoding the peptide according to any one of [1] to [4].
  • [6] A vector comprising the nucleic acid according to [5].
  • [7] A carrier comprising the peptide according to any one of [1] to [4].
  • [8] The carrier according to [7], further comprising a labeling substance or a modifying substance.
  • the carrier according to [8], wherein the labeling substance is a stable isotope, a radioisotope or a fluorescent substance.
  • a pharmaceutical composition comprising the carrier according to any one of [7] to [10] and a physiologically active substance.
  • the pharmaceutical composition according to [11] which is for treating or diagnosing biliary tract cancer.
  • a novel peptide having an accumulation property specific to biliary tract cancer can be provided.
  • biliary tract cancer can be detected simply, with high sensitivity and selectively.
  • 2 is a fluorescence micrograph of various biliary tract cancer cells to which various peptides in Test Example 1 are added.
  • 4 is a fluorescence micrograph of M213 cells to which Peptide 3 and chlorpromazine in Test Example 2 were added. It is a fluorescence micrograph of M213 cell which added Peptide3 and Dinosaur in Test Example 2.
  • 4 is a fluorescence micrograph of M213 cells to which Peptide 3 and EIPA were added in Test Example 2. It is a fluorescence-microscope photograph of M214 cell which added Peptide3 (L body) in Test Example 3 and was culture
  • the present invention provides the following peptide (a) or (b): (A) A peptide consisting of an amino acid sequence containing the sequence represented by SEQ ID NO: 1. (B) A peptide comprising an amino acid sequence comprising a sequence having identity of 60% or more with the sequence represented by SEQ ID NO: 1 and having a specific accumulation property for biliary tract cancer.
  • the peptide of the present embodiment is a novel peptide having an accumulation property specific to biliary tract cancer.
  • the present inventors have found a novel peptide having an accumulation property specific to biliary tract cancer by an in vitro virus (IVV) method, and have completed the present invention.
  • IVV in vitro virus
  • a kind of antibiotic puromycin is bound to the 3 ′ end of mRNA via a PEG (polyethylene glycol) spacer, and cell-free translation reaction is carried out using it as a template, whereby protein and mRNA are purified.
  • a simple mRNA-protein linking molecule IVV covalently linked via is constructed.
  • IVV containing a protein that binds to bait (bait) from this IVV library is picked up in vitro, the mRNA linked to it is reverse-transcribed, amplified by PCR, and the nucleotide sequence is decoded.
  • interacting proteins can be identified in a very small amount (more than 1000 times the sensitivity of mass spectrometry).
  • the peptide of this embodiment includes the following peptide (a).
  • the amino acid sequence represented by SEQ ID NO: 1 in the above (a) is a sequence represented by the following amino acid sequence.
  • LVXGARLVVR SEQ ID NO: 1 [In the amino acid sequence represented by SEQ ID NO: 1 above, X is an isoleucine residue (I), an alanine residue (A), an arginine residue (R), a lysine residue (K) or a histidine residue (H ). ]
  • the peptide (a) has a specific accumulation property for biliary tract cancer. Moreover, even if the peptide of this embodiment is a peptide which consists only of the amino acid sequence represented by sequence number 1, it has accumulation property specific to biliary tract cancer.
  • Bile duct cancer means a malignant tumor that develops from the epithelium of the bile duct.
  • hepatic hilar cholangiocarcinoma hepatic hilar cholangiocarcinoma
  • distal bile duct cancer distal bile duct cancer
  • liver It can be divided into internal bile duct cancer (bile duct cell carcinoma).
  • Gallbladder cancer means a malignant tumor arising from the gallbladder and gallbladder duct.
  • duodenal papilla is composed of the papilla bile duct, papilla pancreas, common duct, and large duodenal papilla
  • duodenal papilla cancer means cancer that has occurred in the above-mentioned site.
  • histopathological classification it refers to adenocarcinoma, adenosquamous carcinoma, and intrahepatic cholangiocellular carcinoma.
  • accumulation specific to biliary tract cancer means a property of being highly absorbed and accumulated in biliary tract cancer cells as compared with normal tissues in vivo and tumor cells of other strains. . As shown in Examples described later, it is presumed that the peptide of this embodiment is absorbed into biliary tract cancer cells by clathrin-dependent endocytosis by dynamin.
  • X is preferably a hydrophilic amino acid residue, and is an arginine residue (R), a lysine residue (K), or a histidine residue (H). Is more preferable, and from the viewpoint of toxicity, an arginine residue (R) is more preferable.
  • amino acid sequence represented by SEQ ID NO: 1 in the above (a) the amino acid sequence represented by SEQ ID NO: 2 and the like can be mentioned.
  • LVRGARLVVR SEQ ID NO: 2
  • the peptide of this embodiment includes the following peptide (b) as a peptide functionally equivalent to the peptide (a).
  • the peptide (b) has 60% or more identity.
  • identity is preferably 70% or more, more preferably 80% or more, further preferably 85% or more, particularly preferably 90% or more, and most preferably 95% or more.
  • the peptide of (b) has a specific accumulation property for biliary tract cancer.
  • the peptide (a) or (b) preferably has a cyclic structure. By being a cyclic structure, it is easily absorbed only into biliary tract cancer cells.
  • the peptide of (a) or (b) may be composed of an L-amino acid, a D-amino acid, or a combination thereof, and is preferably a Retro-Inverso type substituted with a D-form amino acid. .
  • the retro-inverso type makes it difficult to be degraded by intracellular enzymes.
  • the half-life of the peptide (a) or (b) composed only of L-amino acid is 3 to 6 hours, whereas the half-life is increased to 8 to 12 hours due to the Retro-Inverso type. Can do.
  • L-amino acids are naturally occurring amino acids
  • D-amino acids are those in which the chirality of L-amino acid residues is reversed.
  • L-amino acids are naturally occurring amino acids
  • D-amino acids are those in which the chirality of L-amino acid residues is reversed.
  • D-amino acids are those in which the chirality of L-amino acid residues is reversed.
  • in order to enhance the accumulation property specific to biliary tract cancer or may be subjected to chemical modification in order to optimize other physical properties.
  • the peptide (a) or (b) preferably further comprises cysteine residues at the N-terminus and C-terminus.
  • Specific examples include the amino acid sequence represented by SEQ ID NO: 3 below.
  • CLVRGARLLVRC SEQ ID NO: 3
  • the peptide of this embodiment can take a cyclized form by using disulfide bonds between thiol groups possessed by cysteine residues by providing cysteine residues at the N-terminal and C-terminal.
  • nucleic acid encoding peptide In one embodiment, the present invention provides a nucleic acid encoding the peptide described above.
  • a peptide having an accumulation property specific to biliary tract cancer can be obtained.
  • nucleic acid encoding the above peptide for example, a nucleic acid consisting of the base sequence set forth in SEQ ID NO: 4, or 80% or more, such as 85% or more, such as 90% or more, such as the base sequence set forth in SEQ ID NO: 4, for example Examples include nucleic acids including any combination of base sequences encoding each amino acid that is a component of a peptide having 95% or more identity and specific accumulation properties for biliary tract cancer.
  • the base sequence shown in SEQ ID NO: 4 is a nucleic acid base sequence encoding a peptide consisting of the amino acid sequence of SEQ ID NO: 3 above.
  • the present invention provides a vector comprising the nucleic acid described above.
  • a peptide having an accumulation property specific to biliary tract cancer can be obtained.
  • the vector of this embodiment is preferably an expression vector.
  • the expression vector is not particularly limited.
  • plasmids derived from E. coli such as pBR322, pBR325, pUC12, and pUC13
  • plasmids derived from Bacillus subtilis such as pUB110, pTP5, and pC194
  • plasmids derived from yeast such as pSH19 and pSH15
  • viruses such as adenovirus, adeno-associated virus, lentivirus, vaccinia virus, baculovirus, retrovirus, hepatitis virus; and modified vectors thereof.
  • the above-mentioned peptide expression promoter is not particularly limited, and examples thereof include animal cells such as EF1 ⁇ promoter, SR ⁇ promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, HSV-tk promoter, and the like. Promoters for expression using a host cell such as a promoter for expression, cauliflower mosaic virus (CaMV) 35S promoter, REF (rubber elongation factor) promoter, and insect cells such as polyhedrin promoter and p10 promoter. A promoter for expression used as a host can be used. These promoters can be appropriately selected depending on the host expressing the above-mentioned peptide.
  • CaMV cauliflower mosaic virus
  • REF rubber elongation factor
  • the above-described expression vector may further have a multicloning site, an enhancer, a splicing signal, a poly A addition signal, a selection marker, a replication origin, and the like.
  • the present invention provides a carrier comprising a peptide as described above.
  • the target substance can be easily and efficiently transported to the biliary tract cancer.
  • the carrier of this embodiment further includes a labeling substance or a modifying substance.
  • the carrier of this embodiment may include both a labeling substance and a modifying substance.
  • the labeling substance or modifying substance may be physically or chemically bound to the above-described peptide directly or via a linker.
  • the bond may be a coordinate bond, a covalent bond, a hydrogen bond, a hydrophobic interaction, or a physical adsorption, and any of the known bonds, linkers, and bonding methods can be adopted.
  • the labeling substance examples include stable isotopes, radioisotopes, fluorescent substances, positron emission tomography (PET) nuclide, single photon emission tomography (SPECT) nuclide, nuclide Examples thereof include a magnetic resonance imaging (MRI) contrast agent, a computed tomography (CT) contrast agent, and a magnetic substance. Of these, stable isotopes, radioactive isotopes or fluorescent substances are preferred.
  • stable isotopes examples include 13 C, 15 N, 2 H, 17 O, and 18 O.
  • radioisotope examples include 3 H, 14 C, 13 N, 32 P, 33 P, and 35 S.
  • the above peptide may be prepared using a stable isotope-labeled amino acid or a radioisotope-labeled amino acid.
  • amino acids labeled with stable isotopes or radioisotopes 20 kinds of amino acids (alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine , Valine, tryptophan, cysteine, asparagine, glutamine), and any amino acids included in the above-mentioned peptides are not particularly limited.
  • the amino acid may be L-form or D-form, and can be appropriately selected as necessary.
  • the above-mentioned peptide labeled with a stable isotope or a radioisotope is prepared by expressing the above-mentioned vector containing a nucleic acid encoding the above-mentioned peptide in a system in which a stable isotope-labeled amino acid or a radioisotope-labeled amino acid is present. can do.
  • systems in which stable isotope-labeled amino acids or radioisotope-labeled amino acids are present include cell-free peptide synthesis systems in which stable isotope-labeled amino acids or radioisotope-labeled amino acids are present, live cell peptide synthesis systems, etc. .
  • a peptide in addition to a stable isotope-labeled amino acid or a radioisotope-labeled amino acid, a peptide is synthesized using a stable isotope unlabeled amino acid or a radioisotope unlabeled amino acid as a material, or a live cell peptide synthesis system
  • a cell transformed with the above vector containing a nucleic acid encoding the above peptide is cultured in the presence of a stable isotope labeled amino acid or a radioisotope labeled amino acid to thereby contain the above nucleic acid encoding the above peptide.
  • a stable isotope-labeled or radioisotope-labeled peptide described above can be prepared from a vector.
  • Expression of the above-mentioned peptide labeled with a stable isotope or radioisotope using a cell-free peptide synthesis system is performed by the above-mentioned vector containing the nucleic acid encoding the above-mentioned peptide, the above-mentioned stable isotope-labeled amino acid or radioisotope
  • a stable isotope-labeled amino acid or a radioisotope-unlabeled amino acid a cell extract for cell-free peptide synthesis, which is necessary for the synthesis of the above-mentioned peptide labeled with a stable isotope or a radioisotope
  • an energy source high energy phosphate bond-containing material such as ATP, GTP, creatine phosphate, etc.
  • Reaction conditions such as temperature and time can be appropriately selected as appropriate.
  • the temperature is 20 to 40 ° C., preferably
  • cell extract for cell-free peptide synthesis refers to a translation system involved in protein synthesis such as ribosome, tRNA, or a plant cell, animal cell, which contains components necessary for a transcription system and a translation system, It means an extract from fungal cells and bacterial cells. Specific examples include cell extracts such as Escherichia coli, wheat germ, rabbit reticulocyte, mouse L-cell, Ehrlich ascites tumor cell, HeLa cell, CHO cell, and budding yeast. Preparation of such cell extracts is described, for example, in Pratt, J. et al. M.M. Et al., Transcribation and translation-a practical approach (1984), pp.
  • the above cells are disrupted using a French press, glass beads, an ultrasonic disrupter, etc., and a buffer containing several kinds of salts for solubilizing protein components and ribosomes is prepared.
  • a buffer containing several kinds of salts for solubilizing protein components and ribosomes is prepared.
  • it can be performed by homogenizing and precipitating insoluble components by centrifugation.
  • the expression of the above-mentioned peptide labeled with a stable isotope or radioisotope using a cell-free peptide synthesis system is, for example, Premium Expression Kit (manufactured by Cell Free Science) with wheat germ extract, Escherichia coli extraction RTS 100, E. You may carry out using commercially available kits, such as E. coli HY Kit (Roche Applied Science company) and a cell-free Quick (manufactured by Taiyo Nippon Sanso Corporation).
  • the expressed stable isotope-labeled or radioisotope-labeled peptide described above may be appropriately solubilized using a protein denaturant such as guanidine hydrochloride or urea.
  • a protein denaturant such as guanidine hydrochloride or urea.
  • the above-mentioned peptides labeled with a stable isotope or a radioisotope are further prepared by fractionation by fractional centrifugation, sucrose density gradient centrifugation, etc., or by purification using affinity column, ion exchange chromatography, etc. You can also
  • the above-mentioned vector containing a nucleic acid encoding the above-mentioned peptide is introduced into a living cell, and the living cell is nutrientized.
  • stable isotope-labeled amino acids or radioisotope-labeled amino acids stable isotope-labeled peptides or radioisotope-labeled peptides, It can be performed by culturing in a culture solution containing a labeled amino acid or the like.
  • the living cell is not particularly limited as long as it is a living cell capable of expressing the above-described vector containing the nucleic acid encoding the above-mentioned peptide, for example, a mammalian cell line such as a Chinese hamster ovary (CHO) cell, Examples include living cells such as E. coli, yeast cells, insect cells, and plant cells, and E. coli is preferred in view of convenience and cost effectiveness.
  • CHO Chinese hamster ovary
  • the expression of the above-mentioned vector containing the nucleic acid encoding the above-mentioned peptide is incorporated into an expression vector designed so that it can be expressed in each living cell by gene recombination technology, and the expression vector is introduced into the living cell. It can be carried out.
  • introduction of the above-mentioned vector containing a nucleic acid encoding the above-described peptide into a living cell can be performed by a method suitable for the living cell to be used, for example, electroporation method, heat shock method, calcium phosphate method, lipofection Method, DEAE dextran method, microinjection method, particle gun method, method using virus, FuGENE (registered trademark) 6 Transfection Reagent (manufactured by Roche), Lipofectamine 2000 Reagent (manufactured by Invitrogen), Lipofectamine LTX Regent (in vitro) A commercially available transfection reagent such as Lipofectamine 3000 Reagent (manufactured by Invitrogen). Mention may be made of the law and the like.
  • the above-mentioned peptide labeled with a stable isotope label or radioisotope labeled expressed by a living cell peptide synthesis system crushes or extracts a living cell containing the above-mentioned peptide labeled with a stable isotope or radioisotope.
  • the crushing treatment include a physical crushing treatment using a freeze-thaw method, a French press, glass beads, a homogenizer, an ultrasonic crushing device, and the like.
  • Examples of the extraction treatment include extraction treatment using a protein denaturant such as guanidine hydrochloride and urea.
  • the above-mentioned peptide labeled with a stable isotope or a radioisotope is further purified by fractionation using a differential centrifugation method, sucrose density gradient centrifugation, or purification using an affinity column, ion exchange chromatography, etc. It can also be prepared.
  • the above-mentioned peptide labeled with a fluorescent substance is the above-mentioned vector containing a fluorescent substance and a nucleic acid encoding the above-mentioned peptide. May be prepared by the above cell-free peptide synthesis system or living cell peptide synthesis system without using stable isotope-labeled amino acids or radioisotope-labeled amino acids.
  • the above-mentioned peptide labeled with the PET nuclide or SPECT nuclide may be prepared by the above-mentioned cell-free peptide synthesis system or the living cell peptide synthesis system containing the above-mentioned vector containing the nucleic acid encoding the above-mentioned peptide.
  • the MRI contrast agent, CT contrast agent, and magnetic substance include gadolinium, Gd-DTPA, Gd-DTPA-BMA, Gd-HP-DO3A, iodine, iron, iron oxide, chromium, manganese, or a complex thereof, or a chelate thereof. A complex etc. are mentioned.
  • the above-mentioned peptide labeled with an MRI contrast agent, CT contrast agent or magnetic substance is physically or chemically obtained by directly or via a linker between the MRI contrast agent, CT contrast agent or magnetic substance and the above-mentioned peptide.
  • the bond may be a coordinate bond, a covalent bond, a hydrogen bond, a hydrophobic interaction, or a physical adsorption, and any of the known bonds, linkers, and bonding methods can be adopted.
  • the modifying substance examples include sugar chains and polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the target substance can be easily and efficiently absorbed into the biliary tract cancer cells.
  • the above-mentioned peptide modified with the modifying substance may be prepared by physically or chemically bonding the modifying substance and the above-mentioned peptide directly or via a linker.
  • the bond may be a coordinate bond, a covalent bond, a hydrogen bond, a hydrophobic interaction, or a physical adsorption, and any of the known bonds, linkers, and bonding methods can be adopted.
  • the target substance can be appropriately selected depending on the application.
  • the target substance when used for imaging biliary tract cancer, the target substance is provided with the above-described labeling substance as described later.
  • a physiologically active substance when used in the treatment or diagnosis of biliary tract cancer, as described later, a physiologically active substance can be provided as a target substance.
  • the target substance may be physically or chemically bound to the above peptide directly or via a linker.
  • the bond may be a coordinate bond, a covalent bond, a hydrogen bond, a hydrophobic interaction, or a physical adsorption, and any of the known bonds, linkers, and bonding methods can be adopted.
  • a fusion protein containing the target substance and the above-described peptide can be produced by, for example, the following method.
  • a host is transformed with an expression vector containing a nucleic acid encoding a fusion protein.
  • the host is cultured to express the fusion protein.
  • Conditions such as medium composition, culture temperature, time, addition of inducer, etc. can be determined by those skilled in the art according to known methods so that the transformant grows and the fusion protein is efficiently produced.
  • an antibiotic resistance gene is incorporated into an expression vector as a selection marker, a transformant can be selected by adding an antibiotic to the medium.
  • the fusion protein expressed by the host is purified by an appropriate method to obtain the fusion protein.
  • the host is not particularly limited as long as it is a living cell capable of expressing an expression vector containing a nucleic acid encoding a fusion protein.
  • a mammalian cell line such as a Chinese hamster ovary (CHO) cell, or a virus (eg, adeno Virus, adeno-associated virus, lentivirus, vaccinia virus, baculovirus, retrovirus, hepatitis virus etc.), microorganisms such as bacteria (eg E. coli etc.), live cells such as yeast cells, insect cells, plant cells Can be mentioned.
  • an expression vector containing a nucleic acid encoding the above-described fusion protein may be directly introduced into a biliary tract cancer cell or tissue for expression.
  • the present invention provides a pharmaceutical composition comprising the carrier described above and a physiologically active substance.
  • biliary tract cancer can be selectively treated.
  • the “physiologically active substance” is not particularly limited as long as it is effective for treating biliary tract cancer.
  • drugs such as anticancer agents, nucleic acids, antibodies that specifically bind to biliary tract cancer, antibodies Examples thereof include fragments and aptamers.
  • the “physiologically active substance” a molecular target drug having selective cytotoxic activity against biliary tract cancer is preferable.
  • cytotoxic used as a conventional anticancer agent is used. Medicine may be used.
  • the physiologically active substance may be physically or chemically bound to the above carrier directly or via a linker.
  • the bond may be a coordinate bond, a covalent bond, a hydrogen bond, a hydrophobic interaction, or a physical adsorption, and any of the known bonds, linkers, and bonding methods can be adopted.
  • the above-mentioned carrier may contain the above-mentioned labeling substance or modifying substance.
  • nucleic acid examples include siRNA, miRNA, antisense, or an artificial nucleic acid that compensates for these functions.
  • An antibody can be prepared, for example, by immunizing a rodent animal such as a mouse with a peptide derived from biliary tract cancer as an antigen. Further, for example, it can be prepared by screening a phage library. Examples of antibody fragments include Fv, Fab, scFv and the like.
  • Aptamers are substances that have a specific binding ability to biliary tract cancer.
  • Examples of aptamers include nucleic acid aptamers and peptide aptamers.
  • Nucleic acid aptamers having a specific binding ability to biliary tract cancer can be selected by, for example, the systematic evolution of ligand by exponential enrichment (SELEX) method.
  • Peptide aptamers having specific binding ability to biliary tract cancer can be selected by, for example, the two-hybrid method using yeast.
  • the pharmaceutical composition of the present embodiment can be used for biliary tract cancer diagnosis, biliary tract cancer treatment effect diagnosis, pathological analysis, biliary tract cancer treatment, or diagnosis of disease associated with biliary tract cancer, pathological analysis, treatment, and therapeutic effect diagnosis.
  • a diagnostic method for example, PET, SPECT, CT, MRI, an endoscope, a fluorescence detector, and the like can be used.
  • the pharmaceutical composition of the present embodiment takes into account the age, sex, weight, symptoms, treatment method, administration method, treatment time, etc. of the test animal (various mammals including humans or non-human animals, preferably humans). Adjust as appropriate.
  • the pharmaceutical composition of the present embodiment is injected intravenously (Intravenous: iv) by injection, 5 mg or more per kg body weight in a single administration to a test animal (preferably a human).
  • the amount of peptide is preferably administered, more preferably 5 mg or more and 15 mg or less of peptide, and particularly preferably 5 mg or more and 10 mg or less of peptide.
  • the number of administration is preferably 1 to several times per week.
  • Examples of the dosage form include intraarterial injection, intravenous injection, subcutaneous injection, intranasal, intraperitoneal, transbronchial, intramuscular, transdermal, or oral methods known to those skilled in the art. Intravenous injection or intraperitoneal administration is preferred.
  • composition component comprises a therapeutically effective amount of the above-described carrier and bioactive substance, and a pharmaceutically acceptable carrier or diluent.
  • Pharmaceutically acceptable carriers or diluents include excipients, diluents, extenders, disintegrants, stabilizers, preservatives, buffers, emulsifiers, fragrances, colorants, sweeteners, thickeners, flavoring agents. Agents, solubilizers, additives and the like.
  • pharmaceutical compositions in the form of injections, solutions, capsules, suspensions, emulsions, syrups and the like can be prepared.
  • a colloidal dispersion system can also be used as the carrier.
  • the colloidal dispersion system is expected to have an effect of enhancing the in vivo stability of the peptide and an effect of enhancing the transferability of the peptide to a specific organ, tissue, or cell.
  • colloidal dispersion systems include polyethylene glycol, polymer composites, polymer aggregates, nanocapsules, microspheres, beads, oil-in-water emulsifiers, micelles, mixed micelles, and lipids including liposomes. Liposomes and artificial membrane vesicles, which are effective in efficiently transporting peptides to the organs, tissues, or cells, are preferred.
  • Examples of formulation in the pharmaceutical composition of this embodiment include those used orally as tablets, capsules, elixirs, and microcapsules with sugar coating as necessary. Alternatively, those which are used parenterally in the form of sterile solutions with water or other pharmaceutically acceptable liquids, or injectable suspensions. Further, a pharmacologically acceptable carrier or diluent, specifically, sterilized water or physiological saline, vegetable oil, emulsifier, suspension, surfactant, stabilizer, flavoring agent, excipient, vehicle, Examples thereof include those formulated by mixing with a preservative, a binder and the like, and mixing in a unit dosage form generally required for pharmaceutical practice.
  • Additives that can be mixed into tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum, gum arabic, excipients such as crystalline cellulose, swelling such as corn starch, gelatin, and alginic acid Agents, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose or saccharin, flavoring agents such as peppermint, red mono oil or cherry.
  • the above material can further contain a liquid carrier such as fats and oils.
  • Sterile compositions for injection can be formulated according to normal pharmaceutical practice using a vehicle such as distilled water for injection.
  • Aqueous solutions for injection include, for example, isotonic solutions containing physiological saline, glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol and sodium chloride.
  • Suitable solubilizers such as Alcohols, specifically ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 (TM), HCO-50 may be used in combination.
  • oily liquid examples include sesame oil and soybean oil, which may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizing agent.
  • a buffering agent eg, phosphate buffer, sodium acetate buffer, etc.
  • a soothing agent eg, procaine hydrochloride, etc.
  • a stabilizer eg, benzyl alcohol, phenol, etc.
  • an antioxidant etc.
  • an injection it can also be prepared as an aqueous or non-aqueous diluent, suspension, or emulsion as described above.
  • sterilization of injections can be performed by blending filter sterilization with a filter, bactericides, and the like.
  • injectables can be manufactured in the form of business preparation. That is, it can be used as a sterile solid composition by lyophilization, etc., and dissolved in distilled water for injection or other solvent before use.
  • One aspect of the present invention provides a pharmaceutical composition comprising the above carrier and a physiologically active substance for the treatment of biliary tract cancer.
  • One aspect of the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the above-described carrier and bioactive substance, and a pharmaceutically acceptable carrier or diluent.
  • One aspect of the present invention also provides a therapeutic agent for biliary tract cancer comprising the pharmaceutical composition.
  • one aspect of the present invention provides use of the above-described carrier and physiologically active substance for producing a therapeutic agent for biliary tract cancer.
  • Another aspect of the present invention provides a method for treating biliary tract cancer, comprising administering an effective amount of the above carrier and physiologically active substance to a patient in need of treatment.
  • the present invention provides a method for imaging biliary tract cancer using the carrier described above.
  • biliary tract cancer can be detected simply, with high sensitivity and selectively.
  • the carrier described above preferably includes a labeling substance. Furthermore, you may provide the modifier. Examples of the labeling substance and the modifying substance include those described above.
  • the addition amount of the above-mentioned carrier with a labeling substance is preferably 1 ⁇ M or more and 4 ⁇ M or less in the culture solution.
  • it can be evaluated whether or not it is accumulated in the biliary tract cancer cells after 30 minutes or more and 3 hours or less after the addition.
  • the above-mentioned carrier comprising a fluorescent substance as a labeling substance is injected intravenously (Intravenous: iv) with an injection, 1 kg body weight can be obtained per administration to a test animal (preferably human). It is preferable to administer a peptide amount of 5 mg or more, more preferably 5 mg to 15 mg of peptide, and particularly preferably 5 mg to 10 mg of peptide.
  • a PET nuclide or a SPECT nuclide as a labeling substance is injected intravenously (Intravenous: iv) by injection
  • the stable isotope used the PET nuclide
  • what is necessary is just to determine dosage from the radiation dose according to the kind of nuclide for SPECT.
  • PET PET, SPECT, CT, MRI, an endoscope, a fluorescence detector, or the like can be used as a method for detecting the carrier including the labeling substance.
  • Example 1 Peptide synthesis Protein-RNA chimera type random having a 12 amino acid residue peptide as a phenotype and an mRNA coding sequence as a corresponding genotype via a puromycin that is produced independently Using a peptide library (in vitro virus library; IVVL), each peptide (Peptide 1 to 4) shown in Table 1 below was separated and identified according to a known IVV (in vitro virus) method. In addition, each identified peptide derived from IVVL is synthesized with a FITC (Fluoresceinisothiocynate) label and subjected to hydrochloride treatment. R9 (9-residue continuous D-arginine) is a non-selective membrane-permeable peptide that is currently widely used. All of these were obtained by consignment synthesis to Sigma Aldrich Japan (Genosis Division).
  • FITC Fluoresceinisothiocynate
  • MMNK-1 cells For cholangiocarcinoma cells, MMNK-1 cells, hepatoma cells, HeLa cells, U2OS cells, A172 cells, A549 cells, MCF7 cells, GCIY cells, Lovo cells, BxPC3 cells, KPK cells, PC-3 cells, NHDF cells, 10 Culturing was performed using RPMI1640 medium containing% FBS (RPMI1640 medium). Hepatocyte cells were cultured using 5% FBS-containing hepatocyte medium (Hepatocyte medium). HPNE cells were cultured using a CS-C medium kit containing 5% FBS. NuLi-1 cells were cultured using BEGM medium (Bronchial Epidermal Growth Medium, Serum-free). Kidney cells were cultured using a growth medium for normal human kidney epithelial cells (RenaLife Comp Kit). TIME cells were cultured using EBM-2-MV Bullet kit (Endothelial Cell Basal Medium-2 Bullet kit).
  • Example 1 Confirmation test of peptide accumulation in biliary tract cancer cells
  • Peptides 1, 2 and 3 prepared in Example 1 were added to M156 cells, M213 cells, M214 cells and KKU-100 cells in a medium at 4 ⁇ M, respectively. It added so that it might become. The cells were incubated for 60 minutes at 37 ° C. Subsequently, the uptake of each peptide in living cells was visually evaluated with an inverted fluorescence microscope. Remove the culture supernatant to which the peptide was added before microscopic examination, wash 3 times with 1 ⁇ PBS ( ⁇ ), trypsinize, peel off the adherent cells, and immediately transfer to a new 96-well plate. After resuspension, microscopic examination was performed. The results are shown in FIG.
  • Chlorpromazine is an inhibitor that inhibits clathrin-dependent endocytosis.
  • Dinosaur is an inhibitor that inhibits clathrin-dependent endocytosis by dynamin.
  • EIPA is an inhibitor that inhibits macropinocytosis (phagocytosis).
  • Test Example 7 Confirmation test for accumulation of peptides in normal cells derived from various tissues Peptide 3 (4 ⁇ M) and nuclear stain prepared in Example 1 on normal cells derived from various tissues shown in Table 1 above Hoechst (manufactured by Dojindo Co., Ltd.) was added and cultured at 37 ° C. for 120 minutes. Subsequently, the uptake of each peptide in living cells was visually evaluated with an inverted fluorescence microscope by the same method as in Test Example 1. The results are shown in FIG.
  • FIG. 8 reveals that Peptide3 is not taken up by MMNK-1 cells but is taken up only by M156 cells. From this, it was revealed that the peptide of the present invention has specific accumulation properties only in cholangiocarcinoma cells, unlike Tat, which is a conventional cell-permeable peptide.
  • “gal” means gallbladder
  • “liv” means liver
  • “st” means stomach
  • “sp” means spleen
  • “br” means brain
  • “hr” means heart
  • “kd” means kidney
  • “lu” means lung
  • “tumor” means malignant tumor.
  • “Bright Field” is an image taken in a bright field
  • “FITC” is an image taken in a dark field. The upper image is an image when the mouse is opened, the lower left image is an image of various extracted tissues, and the lower right image is an image of sliced various extracted tissues. .
  • FIG. 10 confirmed that Peptide 3 was accumulated only in the gallbladder and malignant tumor.
  • fluorescence was detected only in cholangiocarcinoma cells.
  • Peptide 3 when compared with bile duct cancer cells to which Peptide 3 was added, stronger fluorescence was detected in the bile duct cancer cells to which Peptide 4 was added.
  • fluorescence was also detected in SSP25 cells, OCUG-1 cells, TFK-1 cells and HuCCT1 cells in which no fluorescence was detected with Peptide3. From the above, it was confirmed that Peptide4 which is D body has higher accumulation property in cholangiocarcinoma cells.
  • FIG. 12 “gal” means gallbladder, “liv” means liver, “st” means stomach, “sp” means spleen, “br” means brain, “hr” means heart, “kd” means kidney, “lu” means lung, and “tumor” means malignant tumor.
  • “Bright Field” is an image taken in a bright field
  • “FITC” is an image taken in a dark field.
  • the upper image is an image of a tissue extracted from a mouse added with Peptide3
  • the lower image is an image of a tissue extracted from a mouse added with Peptide4.
  • the left image is an image of various extracted tissues
  • the right image is an image of sliced various tissues.
  • FIG. 13A and 13B are graphs showing the ratios of the fluorescence intensities detected in various tissues when the fluorescence detected in each tissue is quantified and the fluorescence detected in the pancreas is 1 in Test Example 12. It is.
  • FIG. 14 is a graph showing the ratio of the fluorescence intensity detected in the malignant tumor when the fluorescence detected in each tissue is quantified and the fluorescence detected in each tissue is 1. From FIG. 13A and FIG. 13B, in the mouse administered with Peptide3, the fluorescence detected in the malignant tumor was about 8.6 times the fluorescence detected in the liver, whereas in the mouse administered with Peptide4, the malignant tumor was detected. The detected fluorescence was about 45.8 times the fluorescence detected in the liver. In addition, from FIG. 14, when the fluorescence in any tissue was set to 1, it was detected in the malignant tumor in the mouse administered with Peptide 4 rather than the fluorescence detected in the malignant tumor in the mouse administered with Peptide 3. Fluorescence was higher.
  • Peptide 4 which is D body, has higher accumulation in cholangiocarcinoma cells.
  • “Bright Field” is an image taken in a bright field
  • “FITC” is an image taken in a dark field.
  • the upper image is an image when the mouse is opened
  • the lower left image is an image of the extracted liver and malignant tumor
  • the lower right image is a slice of the extracted liver and malignant tumor. It is an image of things.
  • FIG. 15 confirmed that Peptide 4 was accumulated only in the gallbladder and malignant tumor.
  • Peptide 3 has an accumulation property not only in cultured cells but also in cholangiocarcinoma cells derived from cholangiocarcinoma patients.
  • a novel peptide having an accumulation property specific to biliary tract cancer can be provided.
  • biliary tract cancer can be detected simply, with high sensitivity and selectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un nouveau peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire. Le peptide selon la présente invention est (a) un peptide ayant une séquence d'acides aminés contenant une séquence représentée par SEQ ID no : 1, ou (b) un peptide ayant une séquence d'acides aminés contenant une séquence présentant une identité de 60 % ou plus par rapport à la séquence représentée par SEQ ID no : 1, et qui s'accumule spécifiquement dans le cancer du tractus biliaire.
PCT/JP2016/078607 2015-10-01 2016-09-28 Peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire, et son utilisation WO2017057450A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017543480A JP6839447B2 (ja) 2015-10-01 2016-09-28 胆道癌に特異的な集積性を有するペプチド及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015196227 2015-10-01
JP2015-196227 2015-10-01

Publications (1)

Publication Number Publication Date
WO2017057450A1 true WO2017057450A1 (fr) 2017-04-06

Family

ID=58423835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/078607 WO2017057450A1 (fr) 2015-10-01 2016-09-28 Peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire, et son utilisation

Country Status (2)

Country Link
JP (1) JP6839447B2 (fr)
WO (1) WO2017057450A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529333A (ja) * 2006-03-09 2009-08-20 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529333A (ja) * 2006-03-09 2009-08-20 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EISAKU KONDO ET AL.: "Tando Gan Kyushusei Kanjoka Peptide ni yoru Shuyo Imaging", DAI 19 KAI THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER GAKUJUTSU SHUKAI, 31 May 2015 (2015-05-31), pages 90 *
HIGA, M. ET AL.: "Identification of a novel cell-penetrating peptide targeting human glioblastoma cell lines as a cancer-homing transporter", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 457, 2015, pages 206 - 212, XP029165382 *
KAMIDE K ET AL.: "Isolation of novel cell - penetrating peptides from a random peptide library using i n vitro virus and their modifications", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 25, 2010, pages 41 - 51, XP055370739 *
KEN SAITO ET AL.: "Tando Gan Imaging Tool to shite no Saibo Tokasei Peptide no Tansaku", NIPPON BYORI GAKKAI KAISHI, vol. 103, no. 1, 26 March 2014 (2014-03-26), pages 270 *
KEN SAITO ET AL.: "Tando Gan Tokasei Peptide no Tansaku", DAI 18 KAI THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER GAKUJUTSU SHUKAI PROGRAM . SHOROKUSHU, vol. 134, 29 May 2014 (2014-05-29), pages 12 - 2 *
KONDO, E. ET AL.: "Tumour lineage-homing cell - penetrating peptides as anticancer molecular delivery systems", NATURE COMMUNICATIONS, vol. 3, no. 951, 17 July 2012 (2012-07-17), pages 1 - 13, XP055370747 *

Also Published As

Publication number Publication date
JP6839447B2 (ja) 2021-03-10
JPWO2017057450A1 (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
Kuil et al. Imaging agents for the chemokine receptor 4 (CXCR4)
Ding et al. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1
JP2018507865A (ja) 肝細胞へのミトコンドリアの標的化移植
KR20210090157A (ko) 세포 투과 펩티드
WO2019028469A1 (fr) Compositions mitochondriales a polymère fonctionnalisé et procédés d'utilisation dans une transplantation cellulaire et pour modifier un phénotype métabolique
JP6612063B2 (ja) 悪性神経膠腫分子標的ペプチド
WO2017086090A1 (fr) Peptide présentant une accumulation spécifique au cancer du pancréas, et utilisation dudit peptide
WO2017057450A1 (fr) Peptide qui s'accumule spécifiquement dans le cancer du tractus biliaire, et son utilisation
US20220213165A1 (en) Therapeutic peptides
WO2017073485A1 (fr) Peptide doté de propriétés d'agglutination spécifiques vis-à-vis d'un gliome, et application de celui-ci
WO2020195504A1 (fr) Peptide et son utilisation
TWI812706B (zh) 肽以及其使用
CN112979764B (zh) 特异结合人cd47分子的多肽及其用途
JP2020531478A (ja) 新規ペプチド系癌造影剤
CN113784735A (zh) 诊断肺癌的方法
KR20200135224A (ko) 마이셀 구조의 나노 전달체 및 이의 용도
EP4199907A1 (fr) Système d'administration d'antigène ciblé et utilisations associées
TW201627011A (zh) 用於標靶藥物輸送及分子造影之肺癌特異性胜肽

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16851621

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017543480

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16851621

Country of ref document: EP

Kind code of ref document: A1